You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TCbHP

Showing 1 - 12 of 12
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Albumin paclitaxel+trastuzumab+pyrrolitinib,

Active, not recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 23, 2023

Breast Cancer,Her2 Positive Trial in Zhengzhou (Albumin binding paclitaxel+ trastuzumab+ patuzumab, Docetaxel+ carboplatin+

Recruiting
  • Breast Cancer,Her2 Positive
  • Albumin binding paclitaxel+ trastuzumab+ patuzumab
  • Docetaxel+ carboplatin+ trastuzumab + patuzumab
  • Zhengzhou, Henan, China
    Henan cancer hospital
Nov 19, 2022

HER2 Positive Early Breast Cancer Trial in Shanghai (Docetaxel, carboplatin, Trastuzumab)

Recruiting
  • HER2 Positive Early Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Jun 6, 2023

Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, (Epirubicin +

Recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
  • (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jul 24, 2022

HER2-positive Breast Cancer Trial in Shenyang (ARX788, Pyrotinib maleate, Trastuzumab)

Recruiting
  • HER2-positive Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Jun 21, 2022

HER-2 Positive Breast Cancer Trial in Tianjin (TCbHP VS ddEC-THP)

Recruiting
  • HER-2 Positive Breast Cancer
  • TCbHP VS ddEC-THP
  • Tianjin, Tianjin, China
    Breast Oncology, Tianjin Medical University Cancer Institute and
May 15, 2023

Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab, Dalpiciclib)

Not yet recruiting
  • Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital of China Medical University
Dec 2, 2022

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer

Recruiting
  • Breast Cancer
  • Standard Therapy
  • Shenyang, Liaoning, China
    Shengjing Hospital of China Medical University
Jul 30, 2022

Breast Cancer Trial in Nanjing (Neoadjuvant therapy: TCbHPy, Neoadjuvant therapy: TCbHP)

Not yet recruiting
  • Breast Cancer
  • Neoadjuvant therapy: TCbHPy
  • Neoadjuvant therapy: TCbHP
  • Nanjing, China
    the First Affiliated Hospital of Nanjing Medical University
Jul 4, 2022

Breast Cancer Trial in Guandong (pegylated liposomal doxorubicin (PLD), cyclophosphamide (C), trastuzumab (H))

Recruiting
  • Breast Cancer
  • pegylated liposomal doxorubicin (PLD)
  • +5 more
  • Guandong, Guangdong, China
    Sunyat-sen Memorial Hospital
Feb 17, 2022

Breast Cancer Trial in Hangzhou (Docetaxel, Carboplatin, Trastuzumab)

Recruiting
  • Breast Cancer
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 28, 2022

Breast Cancer Trial in Hangzhou (Docetaxel, Carboplatin, Trastuzumab)

Recruiting
  • Breast Cancer
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 28, 2022